GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Angion Biomedica Corp (NAS:ANGN) » Definitions » Gross Margin %

Angion Biomedica (Angion Biomedica) Gross Margin % : 0.00% (As of Mar. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Angion Biomedica Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Angion Biomedica's Gross Profit for the three months ended in Mar. 2023 was $0.00 Mil. Angion Biomedica's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, Angion Biomedica's Gross Margin % for the quarter that ended in Mar. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Angion Biomedica's Gross Margin % or its related term are showing as below:


ANGN's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.38
* Ranked among companies with meaningful Gross Margin % only.

Angion Biomedica had a gross margin of N/A% for the quarter that ended in Mar. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Angion Biomedica was 0.00% per year.


Angion Biomedica Gross Margin % Historical Data

The historical data trend for Angion Biomedica's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Angion Biomedica Gross Margin % Chart

Angion Biomedica Annual Data
Trend Dec12 Dec13 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Margin %
Get a 7-Day Free Trial 90.62 56.96 58.68 98.47 -

Angion Biomedica Quarterly Data
Jun13 Dec13 Mar14 Jun14 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Angion Biomedica's Gross Margin %

For the Biotechnology subindustry, Angion Biomedica's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Angion Biomedica's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Angion Biomedica's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Angion Biomedica's Gross Margin % falls into.



Angion Biomedica Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Angion Biomedica's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=2.3 / 2.301
=(Revenue - Cost of Goods Sold) / Revenue
=(2.301 - 0) / 2.301
=N/A %

Angion Biomedica's Gross Margin for the quarter that ended in Mar. 2023 is calculated as


Gross Margin % (Q: Mar. 2023 )=Gross Profit (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Angion Biomedica  (NAS:ANGN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Angion Biomedica had a gross margin of N/A% for the quarter that ended in Mar. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Angion Biomedica Gross Margin % Related Terms

Thank you for viewing the detailed overview of Angion Biomedica's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Angion Biomedica (Angion Biomedica) Business Description

Traded in Other Exchanges
N/A
Address
7-57 Wells Avenue, Suite 14, Newton, MA, USA, 02459
Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Executives
Jay Venkatesan director, officer: See Remarks C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Allen Nissenson director 601 HAWAII ST., EL SEGUNDO CA 90245
John F. Neylan officer: See Remarks 750 LEXINGTON AVENUE, NEW YORK NY 10022
Gregory S Curhan officer: See Remarks 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Jennifer J Rhodes officer: See Remarks C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Itzhak Goldberg officer: See Remarks 51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
Victor F Ganzi director
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Eisa-abc Llc 10 percent owner C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553